Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 3, 2006, Pages

  Zoma, Willie D ^a,b   Baker, R Scott ^a   Mershon, John L ^a,c   Clark, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Blood flow; Coronary; Estrogen receptor; Raloxifene; Uterine

Indexed keywords

ANTIESTROGEN; DRUG VEHICLE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MESSENGER RNA; RALOXIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEEP; UTERINE ARTERY; UTERINE BLOOD VESSEL; VASCULAR RESISTANCE;

ANIMALS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION; HEMODYNAMIC PROCESSES; OVARIECTOMY; RALOXIFENE; REGIONAL BLOOD FLOW; RNA, MESSENGER; SHEEP; STROKE VOLUME; UTERUS; VASODILATION;

EID: 33748419940     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00666.2005     Document Type: Article

References (47)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, and Wassertheil-Smoller S. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004.
2. Baker RS, Kopernik G, Lang U, and Clark KE. Local coronary infusion of estradiol-17b increases coronary blood flow (Abstract). J Soc Gyn Invest 4: 178A, 1997.
3. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, and Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847-857, 2002.
4. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, and Franceschetti F. Targeted drug delivery in gynecology: the first uterine pass effect. Human Reprod 12: 1073-1079, 1997.
5. Byers MJ, Zangl A, Phernetton TM, Lopez G, Chen DB, and Magness RR. Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of ERα and ERβ levels. J Physiol 565 : 85-99, 2005.
6. Chen DB, Bird IM, Zheng J, and Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 145: 113-125, 2004.
7. Clewell WH, Stys S, and Meschia G. Stimulus summation and tachyphylaxis in estrogen response in sheep. Am J Obstet Gynecol 138: 485-493, 1980.
8. Darkow DJ, Lu L, and White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol Heart Circ Physiol 272: H2765-H2773, 1997.
9. Deitch HR, Mershon JL, and Clark KE. Estrogen receptor beta is the predominant isoform expressed in the brain of adult and fetal sheep. Am J Obstet Gynecol 184: 1077-1079, 2001.
10. Delmas PD, Bjarnason NH, Mitlak B, Ravoux A, Shah A, Huster WJ, Draper M, and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Eng J Med 337: 1641-1647, 1997.
11. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, and Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645, 1999.
12. Figtree GA, Lu Y, Webb CM, and Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100: 1095-1101, 1999.
13. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, and Wenger N. Related cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288: 49-57, 2002.
14. Grohe C, Kahlert S, Loebbert K, Stimpel M, Karas R, Vetter H, and Neyses L. Cardiac monocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 416: 107-112, 1997.
15. Hodges YK, Tung L, Yan XD, Graham D, Horwitz K, and Horwitz L. Estrogen receptors α and β: prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101: 1792-1798, 2000.
16. Kamali P, Muller T, Lang U, and Clapp JF. Cardiovascular responses of perimenopausal women to hormonal replacement therapy. Am J Obstet Gynecol 182: 17-22, 2000.
17. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, and Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci USA 96: 15133-15136, 1999.
18. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, and Schnaper HW. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 94: 1402-1407, 1996.
19. Kojda G, Meyer W, and Noack E. Influence of endothelium and nitrovasodilators on free thiols and disulfides in porcine coronary smooth muscles. Eur J Pharmacol 250: 385-394, 1993.
20. Lang U, Baker RS, and Clark KE. Estrogen-induced increases in coronary blood flow are antagonized by inhibitors of nitric oxide synthesis. Eur J Ob Gyn Reprod Biol 74: 229-235, 1997.
21. Liao WX, Magness RR, and Chen DB. Expression of estrogen receptors-alpha and -beta in the pregnant ovine uterine artery endothelial cells in vivo and in vitro. Biol Reprod 72: 530-537, 2005.
22. Magness RR, Phernetton TM, Gibson TC, and Chen DB. Local uterine blood flow responses to ICI 182,780 in ovariectomized, estradiol-17β treated, intact follicular phase and pregnant sheep. J Physiol 565: 71-83, 2005.
23. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, and Cushman M. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534, 2003.
24. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA 280: 605-613, 1998.
25. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 74: 337-343, 2000.
26. Mershon JL, Baker RS, and Clark KE. Estrogen increases iNOS expression in the ovine coronary artery. Am J Physiol Heart Circ Physiol 283: H1169-H1180, 2002.
27. Morello KC, Wurz GT, and DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinetics 42: 361-372, 2003.
28. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, and Anderson PW. Design and methods of the raloxifene use for the heart (RUTH) study. Am J Cardiol 88: 392-395, 2001.
29. Mosselman S, Polman J, and Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996.
30. Munzel T, Kurz S, Heitzer T, and Harrison DG. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 77: 24C-30C, 1996.
31. Ogita H, Node K, Asanuma H, Sanada S, Kim J, Takashima S, Minamino T, Hori M, and Kitakaze M. Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J Cardiovasc Pharmacol 43: 821-829, 2004.
32. Register TC and Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 64: 187-191, 1997.
33. Rosenfeld CR, Cox BE, Roy T, and Magness RR. Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation. J Clin Invest 98: 2158-2166, 1996.
34. Rosselli M, Imthurn B, Keller PJ, Jackson EK, and Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta estradiol and norethisterone acetate: a two year follow-up study. Hypertension 25: 848-853, 1995.
35. Sar M and Welsch F. Differential expression of the estrogen receptor-β and estrogen receptor-α in the rat ovary. Endocrinology 140: 963-971, 1999.
36. Sarrel PM, Nawaz H, Chan W, Fuchs M, and Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 188: 304-309, 2003.
37. Sato M, Glasebrook AL, and Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Met 12: S9-S20, 1994.
38. Simoncini T and Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85: 2966-2969, 2000.
39. Simoncini T, Genazzani AR, and Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105: 1368-1373, 2002.
40. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, and Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325: 756-762, 1991.
41. Van Buren GA, Yang D, and Clark KE. Estrogen-induced uterine vasodilation is antagonized by L-nitroarginine methyl ester, and inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 167: 828-833, 1992.
42. Wakeling AE. Use of pure antiestrogens to elucidate the mode of action of estrogens. Biochem Pharmacol 49: 1545-1549, 1995.
43. Wakeling AE, Dukes M, and Bowler J. A potent specific antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991.
44. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, and Anderson PW. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 85: 214-218, 2000.
45. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, and Moncada S. Induction of calcium-dependent nitric oxide synthetase by sex hormones. Proc Natl Acad Sci USA 91: 5212-5216, 1994.
46. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2888: 321-333, 2002.
47. Zoma WD, Baker RS, and Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 182: 521-528, 2000.